Business transformation through DX
First written in FY2023-Q1. 3 of 7 entries say "Advanced", first in FY2025-H1. Latest entry: FY2027-H1.
138 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「At ArkMS株式会社, the company is working to expand and strengthen CRO solutions, strengthen TSCS collaboration, and develop Ark Platform, a system that collects and utilizes data within the Group related to the limited distribution of specialty pharmaceuticals and other products. It is also making maximum use of AI to improve productivity and advancing initiatives to establish its management foundation.」
Business transformation through DX has taken concrete form in the development of a data collection and utilization system for products with restricted distribution and productivity improvements in the CRO business using AI. - FY2026-H1AdvancedAnnual report
「While pursuing operational improvements through the use of product services, the company aims to develop sales activities proactively」
The company identified sales-operations improvement through the use of product services as a specific application area for business transformation through DX and digital technology. - FY2025-H1AdvancedAnnual report
「アルフレッサ also introduced products provided by セールスフォース・ジャパン (head office: Chiyoda-ku, Tokyo) and built the “Vaccine Supply Optimization Platform” (service name: ワクチンぷらっと), which improves convenience for people wishing to be vaccinated and medical institutions and enables vaccine supplies to be matched to demand.」
Business transformation through DX has progressed to the development of a platform supporting vaccine appointment management and supply in line with demand. - FY2024-Q1RestatedAnnual report
「In the wholesale business for prescription pharmaceuticals and other products, we are pursuing the key initiatives set out in the 22-24 medium-term management plan—“strengthening existing businesses,” “monetization through business transformation,” and “optimization, efficiency and standardization across the group”—in order to concentrate resources on specialty areas and medical products and transform the business through DX.」
The company continues to focus on specialty products and medical products in the wholesale business for prescription drugs and other medical products, while pursuing business transformation through DX. - FY2023RestatedAnnual report
「We will create new value and address customers’ challenges by using a range of digital tools, including digital health and health tech. We will also take our activities connecting people involved in healthcare to a new stage through DX initiatives and other measures, improve customer satisfaction, and take on new business areas related to health and medicine.」
The company reconfirmed its policy of using DX in the wholesale, manufacturing and healthcare-related fields to create new value through digital health and health tech. - FY2023-Q2RaisedAnnual report
「In the pharmaceutical and other manufacturing business, the Group is pursuing the following priority initiatives under the 22-24 Medium-Term Plan, with the aim of “Building the foundation for the next generation—Maximizing corporate value”: “Safe, secure and reliable manufacturing,” “Initiatives to realize total supply chain services,” and “New initiatives leveraging digital technology.”」
The scope of business transformation through DX expanded from the wholesale business for prescription drugs and other medical products to the manufacturing business for pharmaceuticals and other products, and was explicitly included in the 22-24 Medium-Term Management Plan as a "new initiative leveraging digital technology." - FY2023-Q1First statedAnnual report
「To concentrate resources on specialty areas and medical products and transform the business through DX」
The 22-24 Medium-Term Management Plan explicitly identifies DX as a means of transforming the wholesale business for prescription drugs and other medical products.